Clinical trials: Head and Neck Cancers
Esophageal Fistula, Esophageal Neoplasms
Removal of the Evolution® Esophageal Stent - Fully Covered
The CLARITY study is a clinical trial approved by US FDA to study the removal of the Evolution® Esophageal Stent-Fully Covered in malignant and benign indications.
- Conditions
- Esophageal Fistula, Esophageal Neoplasms, Esophageal Perforation, Esophageal Stenosis
- Trial name
- CLARITY (NCT01900691)
- Testing
- Evolution® Esophageal Stent - Fully Covered
- Where
- 11 sites in United States
- Volunteers
- 130 people
- Sponsor
- Cook Group Incorporated
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Head and Neck Cancer
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
The goal of this clinical research study is to learn if giving the new drug, Tarceva® (OSI-774), in combination with Platinol® (cisplatin) and Taxotere® (docetaxel) is effective in the treatment of metastatic or recurrent head…
- Trial name
- NCT00076310
- Testing
- Docetaxel, OSI-774, Cisplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer, Thyroid Cancer, Papillary
Circulating Biomarkers to Identify Thyroid Cancer
This study aimed to identify the potential circulating biomarkers of protein, mRNAs, and long non-coding RNAs (lncRNAs) to differentiate the papillary thyroid cancers from benign thyroid tumors.
- Conditions
- Thyroid Cancer, Thyroid Cancer, Papillary, Benign Thyroid Tumor
- Trial name
- NCT04594720
- Testing
- Identification group, Validation group
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Chang Gung Memorial Hospital
Primary Esophageal Carcinoma
Angiogenic Factor Expression During Fractionated Irradiation
The main question of this study is if and when VEGF (vascular endothelial growth factor) expression in the tumor is upregulated during chemoradiation and if bevacizumab inhibits subsequent vessel growth in the tumor.
- Trial name
- NCT02072720
- Testing
- Bevacizumab
- Where
- 3 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Head and Neck Neoplasm
Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Locoregional failure remains the principal mode of mortality in head and neck squamous cell carcinoma (HNSCC) treated with conventional chemoradiation therapy.
- Trial name
- DEHART (NCT04477759)
- Testing
- 50 Gy Radiation Therapy, 55 Gy Radiation Therapy, 60 Gy Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical College of Wisconsin
Squamous Cell Carcinoma of the Head and Neck
Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN
The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.
- Trial name
- NCT03880396
- Testing
- hypofractionated Rth with platinol
- Where
- Egypt
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Assiut University
Nasopharyngeal Carcinoma
Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and Penpulimab ± Anlotinib in neoadjuvant therapy combined with Penpulimab in adjuvant therapy of locoregionally advanced…
- Trial name
- NCT05193617
- Testing
- GP+Penpulimab+Anlotinib, GP+Penpulimab
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Nasopharyngeal Carcinoma
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)
The objective of this study is to characterize genes associated either with susceptibility or resistance to the development nasopharyngeal carcinoma (NPC) in a Chinese population where the incidence of NPC is as high as 50 in…
- Trial name
- NCT00341146
- Where
- China
- Volunteers
- 6,490 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Cancer of the Head and Neck
Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
The standard treatment for head and neck cancer relapses in previously irradiated patients is controversial. Reirradiation has had some success, but many patients still die from their disease.
- Trial name
- NCT00934518
- Testing
- Radiation, Cetuximab
- Where
- United States
- Sponsor
- Milton S. Hershey Medical Center
Squamous Cell Carcinoma Of The Head And Neck
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
This is a single-arm, non-masked, open-label, Phase II study of cetuximab + dasatinib in recurrent Squamous Cell Carcinoma of The Head and Neck (SCCHN) that has recurred after cetuximab-containing therapy (please see attached…
- Trial name
- NCT01488318
- Testing
- Cetuximab, Dasatinib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Julie E. Bauman, MD, MPH
Thyroid Neoplasms, Genetic Susceptibility
Genetic Susceptibility to Radiation Induced Thyroid Cancer
Case control on thyroid cancer occuring in a cohort of 7300 subjects treated during their childhood, mostly by radiotherapy, for a skin Angioma at Gustave Roussy, Villejuif France between 1947 and 1973.
- Conditions
- Thyroid Neoplasms, Genetic Susceptibility, Radiation Exposure
- Trial name
- NCT04139096
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Head and Neck Cancer, Xerostomia Following Radiotherapy
Laser Acupoints Stimulation on Xerostomia Related Chemoradiotherapy for Head and Neck Cancer Patients
The purpose of the study is to evaluate to effect of LASER acupoints stimulations on xerostomia patients during chemoradiation therapy after head and neck cancer.
- Trial name
- NCT07029854
- Testing
- Medical treatment, LASER acupoints therapy, Pseudo-LASER acupoints therapy
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Cairo University
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Squamous Cell Carcinoma of the Oral Cavity
Contribution of Residual Tumour DNA Testing on the Surgical Bed
The aim of this study is to evaluate the interest of residual tumour DNA research in the operating bed after squamous cell carcinoma excision.
- Trial name
- MARGINS (NCT05934929)
- Testing
- Circulating tumor DNA detection
- Where
- 2 sites in France
- Volunteers
- 31 people
- Sponsor
- Centre Henri Becquerel
Head and Neck Cancer
Efficacy of Prophylactic Treatment With Antibiotics During Concomitant Chemoradiotherapy in Patients With Head and Neck Cancer to Prevent Aspiration Pneumonia
Patients with locally advanced head and neck cancer treated with chemo-radiotherapy have (during and shortly after this treatment) a high risk of developing pneumonia by aspiration.
- Trial name
- PANTAP (NCT01598402)
- Testing
- amoxicillin/clavulanic acid suspension
- Where
- 6 sites in Netherlands
- Volunteers
- 106 people
- Sponsor
- Radboud University Medical Center
Thyroid Nodules
Elastography Interest in the Management of Thyroid Nodules
Define an ultrasound/elastography benignity criteria in strategy management of a patient population carries one or more thyroid nodules.
- Trial name
- SWETHY (NCT01335828)
- Testing
- Medical ultrasound device (ShearWave system)
- Where
- France
- Volunteers
- 125 people
- Sponsor
- AdministrateurCIC
Esophageal Cancer, Non-small Cell Lung Cancer
Early Prediction of Pathology Response of Chemoradiotherapy With FLT PET
The goal of this research study is to learn if a new type of PET scan (18F-FLT) can help to better detect changes of tumor growth rate (or how active) in esophagus cancer and lung cancer Researchers will study at what time during…
- Trial name
- NCT01065818
- Testing
- Fluoro-L-Thymidine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.